

# UBIQUITIN PROTEASOME: GLOBAL MARKETS FOR RESEARCH TOOLS, DIAGNOSTICS AND DRUG DISCOVERY



PHM066B  
June 2013

Marianna Tcherpakov  
*Project Analyst*

ISBN: 1-56965-435-2

**bcc** | Research  
Market Forecasting

**BCC Research**  
49 Walnut Park, Building 2  
Wellesley, MA 02481  
866-285-7215, 781-489-7301  
[www.bccresearch.com](http://www.bccresearch.com)  
Custom Reports:  
[carol.laverty@bccresearch.com](mailto:carol.laverty@bccresearch.com)

**TABLE OF CONTENTS**

<b>TOPIC</b>	<b>PAGE NO.</b>
CHAPTER 1 INTRODUCTION	2
STUDY GOALS AND OBJECTIVES	2
REASONS FOR DOING THIS STUDY	2
SCOPE AND FORMAT	2
METHODOLOGY AND INFORMATION SOURCES	3
INTENDED AUDIENCE	3
ANALYST CREDENTIALS	3
RELATED REPORTS	3
BCC ON-LINE SERVICES	4
DISCLAIMER	4
CHAPTER 2 SUMMARY	6
<i>SUMMARY TABLE GLOBAL MARKET FOR UBIQUITIN PROTEASOME RESEARCH AND DEVELOPMENT, THROUGH 2018 (\$ MILLIONS)</i>	7
<i>SUMMARY FIGURE GLOBAL MARKET FOR UBIQUITIN PROTEASOME RESEARCH AND DEVELOPMENT, 2010-2018 (\$ MILLIONS)</i>	7
CHAPTER 3 SCIENTIFIC BACKGROUND AND SIGNIFICANCE OF UBIQUITIN PROTEASOME RESEARCH	9
OVERVIEW	9
UBIQUITIN PROTEASOME SYSTEM: ITS MAJOR COMPONENTS AND ENZYMATIC PROCESS	9
<i>FIGURE 1 SCHEMATIC REPRESENTATION OF ENZYMATIC STEPS IN UBIQUITINATION REACTION</i>	10
<i>FIGURE 2 HIERARCHICAL STRUCTURE OF UBIQUITINE PROTEASOME SYSTEM</i>	10
<i>TABLE 1 ENZYMATIC COMPONENTS OF UBIQUITINATION/ DEUBIQUITINATION REACTION</i>	11
Chain Topology and its Significance in Cellular Function	11
PROTEASOME MACHINERY	12
20S Core Particle	12
19S Core Particle	13
Protein Degradation Process	13
Proteasome as a Target for Drug Discovery	14
UBIQUITIN DOMAIN PROTEINS AND UBIQUITIN-LIKE MODIFIERS	15
<i>TABLE 2 UBIQUITIN LIKE MODIFIERS (UBLs), THEIR FUNCTION AND ASSOCIATED SUBSTRATES</i>	15
CHAPTER 4 UBIQUITIN PROTEASOME SYSTEM AND DRUG DISCOVERY	18
PROTEASOME MACHINERY IN DRUG DISCOVERY	18
OVERVIEW	18
Velcade: the First Ubiquitin Proteasome System Product	18
Chemical Structure of Velcade and Its Mechanism of Action	18
<i>FIGURE 3 CHEMICAL STRUCTURE OF BORTEZOMIB</i>	19
Pharmacodynamics, Administration and Side Effects	19
Velcade Sales Market	21
<i>TABLE 3 U.S. STATISTICS FOR HEMATOLOGICAL MALIGNANCIES, 2011</i>	21
Multiple Myeloma Symptoms and Treatment	21

<b>TOPIC</b>	<b>PAGE NO.</b>
<i>TABLE 4 MARKET SIZE FOR MULTIPLE MYELOMA DRUG MARKET, THROUGH 2018 (\$ BILLIONS)</i>	22
NHL and Mantle Cell Lymphoma	23
Treatments for Mantle Cell Lymphoma and Other NHL	23
Current Major Market Participants in MM Treatment and Sales Forecast	24
Millennium Pharmaceuticals (a Subsidiary of Takeda)	24
<i>TABLE 5 EXAMPLE OF COST OF SIDE EFFECT FOR CHEMOTHERAPY TREATMENT IN 2006 IN U.S. PER PATIENT (\$ THOUSANDS)</i>	25
<i>TABLE 6 U.S. AND WORLDWIDE NET SALES FOR VELCADE, THROUGH 2018 (\$ MILLIONS)</i>	26
<i>FIGURE 4 U.S. AND WORLDWIDE NET SALES FOR VELCADE, 2009-2018 (\$ MILLIONS)</i>	26
Celgene	27
Revlimid	27
Thalomid	28
<i>TABLE 7 NET SALES FOR REVLIMID AND THALOMID, THROUGH 2018 (\$ MILLIONS)</i>	28
<i>FIGURE 5 NET SALES FOR REVLIMID AND THALOMID, 2009-2018 (\$ MILLIONS)</i>	29
Pomalyst	29
Onyx Pharmaceuticals	30
Kyprolis	30
<i>TABLE 8 NET SALES FOR KYPROLIS, THROUGH 2018 (\$ MILLIONS)</i>	31
<i>FIGURE 6 NET SALES FOR KYPROLIS, 2011-2018 (\$ MILLIONS)</i>	31
Market Shares of Millennium/Takeda, Celgene and Other Companies' Drugs	32
<i>TABLE 9 MARKET SHARE BETWEEN CELGENE AND MILLENIUM PHARMACEUTICALS/TAKEDA AND OTHER DRUG COMPANIES IN 2009, 2012 AGAINST POSSIBLE MARKET SHARE IN 2016 AND AFTER</i>	33
New Indications for Velcade and Second-Generation Proteasome Inhibitors from Millenium/Takeda	34
<i>TABLE 10 CURRENT R &amp;D ACTIVITY IN UBIQUITIN/PROTEASOME RESEARCH IN MILLENIUM PHARMACEUTICALS</i>	35
COMPANIES WORKING ON SECOND-GENERATION PROTEASOME INHIBITORS	36
Current Market Participants	36
<i>TABLE 11 COMPANIES WITH CURRENT R&amp;D IN PROTEASOME INHIBITION AS A DRUG TARGET</i>	37
Millennium Pharmaceuticals (a Subsidiary of Takeda)	37
Onyx Pharmaceuticals	37
Onx- 0912/Oprozomib	37
Onx-0914	38
<i>TABLE 12 GENERAL MARKET WORTH FOR AUTOIMMUNE DISORDERS: LUPUS, RHEUMATOID ARTHRITIS AND IBD IN 2010 (\$ BILLIONS)</i>	38
Cephalon (Teva)	38
CEP-18770/Delanzomib	38
Nereus Pharmaceuticals	39
NPI-0052/Marizomib	39
19S Inhibitors as Therapeutic Targets	39
ADDITIONAL MARKETS AND POTENTIAL THERAPEUTIC APPLICATIONS FOR PROTEASOME ACTIVATORS/INHIBITORS	40

<b>TOPIC</b>	<b>PAGE NO.</b>
Proteasome Inhibitors in Treatment of Organ Transplant Patients	40
Autoimmune Diseases and Proteasome Inhibition	40
Anti - Inflammatory Activity of Proteasome Inhibitors	41
<i>TABLE 13 ACTIVITY OF PROTEASOME INHIBITORS IN ANIMAL MODELS FOR AUTOIMMUNE AND INFLAMMATORY DISEASES</i>	41
Treatment of Reperfusion Injury after Stroke	42
Stimulation of Bone and Hair Growth by Proteasome Inhibitors	42
<i>TABLE 14 MARKET SIZE FOR HAIR LOSS TREATMENT IN THE U.S. (\$ BILLIONS)</i>	43
Proteasome Activity Modulators as Skin Care and Cosmetic Treatment	43
<i>TABLE 15 GLOBAL MARKET SIZE FOR ANTI-AGING PRODUCTS (\$ BILLIONS)</i>	44
Proteasome Inhibitors as Anti-infectives	44
<i>TABLE 16 STATISTICS FOR TUBERCULOSIS INFECTION WORLDWIDE AND IN THE U.S., 2009 (MILLIONS)</i>	45
<i>TABLE 17 POTENTIAL MARKET WORTH FOR TUBERCULOSIS DRUG TREATMENT, 2009-2017 (\$ MILLIONS)</i>	46
Proteasome Inhibition as Dry Eye Treatment	46
<i>TABLE 18 MARKET SIZE FOR DRY EYE TREATMENT, 2009 AND 2013 (\$ BILLIONS)</i>	46
UBIQUITINATION ENZYMES AS A TARGET FOR DRUG DISCOVERY	47
E1 LIGASE AS A TARGET FOR DRUG DISCOVERY	47
<i>TABLE 19 CURRENT DRUG DISCOVERY FOR E1 INHIBITORS</i>	47
Pyr-41, the First E1 Inhibitor	47
Nae-E1 Ligase for Neddylation as a Drug Target	48
MLN4924- NAE-1 Inhibitor by Millennium Pharmaceuticals (Takeda)	48
Benzothiazole/Thiazole Pyridine	49
E2 LIGASE AS A TARGET FOR DRUG DISCOVERY	49
<i>TABLE 20 E2S AS A DRUG DISCOVERY TARGET AND ITS MARKET POTENTIAL (\$ BILLIONS)</i>	51
Blood Disorders Market for E2s	51
Ube2T: Fanconi Anemia	51
Spectrin Sickle-Cell Disease (SCD)	51
<i>TABLE 21 MARKET POTENTIALS FOR SCA TREATMENT</i>	52
Oncology and the Immune Disorders Market for E2s	52
Role of UbcH10 in Cancer	52
Ubc13 Cancer/Immune Disorders	53
Neurodegenerative Disorders Market for E2s	54
E2-25K Alzheimer's and Huntington's Diseases	54
E2s as Target for Plant Biotechnology	54
E3 LIGASES AS A DRUG DISCOVERY TARGET	54
<i>TABLE 22 COMPANIES THAT WORK ON E3 LIGASES AS A DRUG TARGET</i>	55
Overview of Companies Working on E3 Ligases as Drug Targets	55
Aegera Therapeutics (Pharmascience)	55
AEG35156	55
AEG40826 (HGS1029)	56
AEGXXXX	57
Amgen	57
Aprea AB	58
Ascenta Therapeutics	58

<b>TOPIC</b>	<b>PAGE NO.</b>
Celgene	59
Elan Pharmaceuticals	59
Genentech (Hoffmann La Roche)	59
Hoffman La Roche	60
Johnson & Johnson (Ortho Biotech Oncology Research and Development)	61
Novartis	61
Priaxon AG	62
Progenra	62
Proteologics	63
Rigel Pharmaceuticals	64
TetraLogic Pharmaceuticals	64
HDM2 as a Target for Drug Discovery	64
<i>TABLE 23 DRUG DISCOVERY APPROACH FOR P53 STUDIES</i>	65
<i>TABLE 24 COMPANIES WITH R&amp;D IN P53 GENE THERAPY</i>	66
Head and Neck Cancer as a Market Target for p53 Therapy	66
Ovarian Cancer as a Market Target for p53 Therapy	67
<i>TABLE 25 U.S. STATISTICS AND GLOBAL MARKET SIZE FOR HEAD AND NECK AND OVARIAN CANCERS, 2009 (\$ MILLIONS)</i>	67
HDM2-p53 Strategy for Drug Discovery	67
<i>TABLE 26 STRATEGIES FOR HDM2-P53 DRUG DISCOVERY</i>	68
<i>TABLE 27 LIST OF COMPANIES AND DRUG CANDIDATES IN HDM2/P53 DRUG DISCOVERY</i>	69
The IAP Family as a Target for Drug Discovery	70
<i>TABLE 28 CURRENT COMPANIES WITH R&amp;D PROGRAM IN IAP DRUG DISCOVERY</i>	71
<i>TABLE 29 POTENTIAL MARKETS SIZE FOR IAPS DRUG DISCOVERY (\$ BILLIONS)</i>	73
Additional E3 Ubiquitin Ligases as Targets for Drug Discovery	73
<i>TABLE 30 LIST OF E3 UBIQUITIN LIGASES IN DRUG DISCOVERY</i>	73
APC Ligase Complex	74
SCF Complex	74
TRAF6	75
MuRF1	75
IDOL	75
Parkin	76
HRD1	76
<i>TABLE 31 STATISTICS FOR RA IN THE U.S. AND GLOBAL ESTIMATE FOR RA MARKET, 2009 AND 2030 (\$ BILLIONS)</i>	76
POSH1	77
SMURF1	77
<i>TABLE 32 STATISTICS FOR OSTEOPOROSIS IN THE U.S. AND GLOBAL ESTIMATE FOR OSTEOPOROSIS MARKET (\$ BILLIONS)</i>	77
Cereblon	78
Midline-1	78
RNF146 and Bmi/Ring1B	78
<i>TABLE 33 POTENTIAL MARKETS FOR CURRENT PROJECTS IN E3 LIGASE DRUG DISCOVERY (\$ BILLIONS)</i>	79
Additional E3 Ligases as Potential Drug Targets	79
<i>TABLE 34 ADDITIONAL E3 LIGASES AS POTENTIAL DRUG DISCOVERY TARGETS</i>	79
A07	80

<b>TOPIC</b>	<b>PAGE NO.</b>
Trim25	80
BRCA1	80
pVHL	80
E6-AP	80
LUBAC	80
<i>TABLE 35 BREAST CANCER STATISTICS IN WOMEN IN THE U.S., 2009 (NUMBER OF NEW CASES)</i>	81
<i>TABLE 36 MARKET FOR BREAST CANCER THERAPEUTICS, THROUGH 2016 (\$ BILLIONS)</i>	82
Companies with a Wide General Platform for Drug Discovery in Ubiquitin-proteasome Systems	82
DEUBIQUITINASES AS A TARGET FOR DRUG DISCOVERY	83
OVERVIEW	83
<i>TABLE 37 DEUBIQUITINASES AND THEIR ROLE IN CLINICAL CONDITIONS</i>	83
POTENTIAL MARKETS BY DISEASE TYPE	84
Cancer	84
Neurodegeneration	84
Hematological Disorders	85
Virus Infections	85
Bacterial Infections	85
<i>TABLE 38 EXAMPLES OF POTENTIAL MARKETS FOR DUBS DRUG DISCOVERY (\$ BILLIONS)</i>	86
<i>TABLE 39 EXAMPLES OF DUBS INHIBITORS AND THEIR TARGETS</i>	87
COMPANIES THAT WORK ON DUBS AS A DRUG TARGET	88
<i>TABLE 40 COMPANIES WORKING ON DUBS AS DRUG TARGET</i>	89
CellCentric	89
Cleave Biosciences	89
Genentech	90
Hybrigenics	90
Mission Therapeutics	90
Novartis	91
<i>TABLE 41 STATISTICS AND COST OF MEDICAL CARE IN LUNG AND COLON CANCER IN THE U.S., 2009 (\$ BILLIONS)</i>	91
Progenra	92
Proteostasis Therapeutics	92
UBIQUITIN-LIKE MODIFIERS AS TARGETS FOR DRUG DISCOVERY	93
Sumoylation Modification as a Drug Target Strategy	93
<i>TABLE 42 ENZYMATIC MACHINERY OF SUMOYLATION</i>	94
ISG15 Modification as a Drug Target Strategy	94
NEDDYLATION MODIFICATION AS A DRUG TARGET STRATEGY	95
CHAPTER 5 THE UBIQUITIN PROTEASOME SYSTEM AS A DIAGNOSTIC TOOL	97
OVERVIEW	97
<i>TABLE 43 GLOBAL BIOMARKERS MARKET, THROUGH 2015 (\$ BILLIONS)</i>	98
<i>TABLE 44 WORLDWIDE MARKET FOR BIOMARKERS ACCORDING TO DIFFERENT RESEARCH AREAS, 2013 (\$ BILLIONS/%)</i>	98
CANCER BIOMARKERS	98
CARDIOVASCULAR DISEASE BIOMARKERS	99
CNS DISORDERS BIOMARKERS	100

<b>TOPIC</b>	<b>PAGE NO.</b>
THE UBIQUITIN PROTEASOME SYSTEM AS A POTENTIAL DIAGNOSTIC TOOL	100
<i>TABLE 45 ANALYSIS OF SCIENTIFIC PUBLICATION ON UBIQUITIN PROTEASOME SYSTEM</i>	101
UPS and Cancer Diagnostics	101
<i>TABLE 46 MARKET FOR BREAST CANCER DIAGNOSTICS, THROUGH 2016 (\$ BILLIONS)</i>	103
UPS and Immune Disorder Diagnostics	103
<i>TABLE 47 WORLDWIDE STATISTICS AND GLOBAL MARKET SIZE FOR MULTIPLE SCLEROSIS AND RHEUMATOID ARTHRITIS</i>	103
<i>TABLE 48 MARKET FOR IMMUNE DISORDERS DIAGNOSTICS (\$ BILLIONS)</i>	105
UPS and Neurodegenerative Disorders Diagnostics	105
<i>TABLE 49 MARKET SIZE FOR REPRESENTATIVE NEURODEGENERATION DISORDERS AND STATISTICS OF INCIDENCE IN THE U.S.</i>	106
<i>TABLE 50 NET SALES OF REQUIP, 2010-2012 (\$ MILLIONS)</i>	107
<i>TABLE 51 NET SALES OF NAMENDA IN THE LAST THREE YEARS, 2010-2012 (\$ MILLIONS)</i>	108
<i>TABLE 52 STATISTICS FOR HUNTINGTON CONDITION IN THE U.S. AND GLOBAL MARKET SIZE FOR HUNTINGTON'S DISEASE</i>	108
UPS as a Diagnostic Tool in Other Pathologies	109
Inflammatory Bowel Disease	109
<i>TABLE 53 STATISTICS AND COST OF IBD IN THE U.S.</i>	110
Biomarkers for Hepatocellular Carcinoma (HCC) in Cirrhosis Patients	110
<i>TABLE 54 STATISTICS AND COST OF HCC IN USA</i>	110
CHAPTER 6 REAGENTS AND ASSAY DEVELOPMENT FOR UPS RESEARCH AND DRUG DISCOVERY	113
OVERVIEW	113
CURRENT MARKET PARTICIPANTS	113
<i>TABLE 55 COMPANIES INVOLVED IN MARKETING OF RESEARCH TOOLS FOR UPS, NUMBER OF PRODUCTS AND REVENUE OF THE COMPANY, 2010 (UNITS/\$ MILLIONS)</i>	113
Boston Biochem	114
Enzo Life Sciences	114
LifeSensors	114
Life Technologies (Thermo Fisher Scientific)	114
Meso Scale Discovery	115
Millipore (EMD4Biosciences)	115
UbiQ	115
Ubiquigent	115
Additional Market Participants	116
<i>TABLE 56 EXAMPLE OF COMMON UPS REAGENTS PRICES IN MAJOR SUPPLIERS OF UPS REAGENT TOOL COMPANIES (\$)</i>	117
<i>FIGURE 7 EXAMPLE OF COMMON UPS REAGENTS PRICES IN MAJOR SUPPLIERS OF UPS REAGENT TOOL COMPANIES (\$)</i>	117
ASSAY DEVELOPMENT FOR UPS DRUG DISCOVERY	117
<i>TABLE 57 PROVIDERS OF SCREENING ASSAY TOOLS</i>	118
Current Market Participants in Assay Development for UPS Research	118
LanthaScreen Technology for Ubiquitination/Deconjugation Assays	118
AlphaScreen Approach for Ubiquitination/Deconjugation Assays	119

<b>TOPIC</b>	<b>PAGE NO.</b>
Cisbio Bioassays	119
Meso Scale Discovery	120
LifeSensors	120
Promega	121
BioGenova	121
Ubiquigent	121
Ubiquitin as a Research Tool for Other Drug Discovery Opportunities	122
<i>TABLE 58 COMPANIES SELLING UBIQUITIN AND UBIQUITIN-LIKE MODIFIERS AS REAGENT TOOL FOR OTHER DRUG DISCOVERIES APPLICATIONS</i>	123
Scil Proteins	123
Dualsystems Biotech	124
LifeSensors	124
Life Technologies (Thermo Fisher Scientific)	125
<b>CHAPTER 7 MILESTONES IN UBIQUITIN-PROTEASOME MARKET DEVELOPMENT AND SIGNIFICANCE OF PATENTS</b>	127
<b>MAIN MILESTONES IN UBIQUITIN-PROTEASOME MARKET DEVELOPMENT</b>	127
<i>TABLE 59 SCIENTIFIC AND TECHNOLOGICAL BREAKTHROUGHS IN UPS, 1977-2012</i>	127
PROTEASOME DISCOVERY AS A SCIENTIFIC BREAKTHROUGH	128
NEW DEVELOPMENTS IN UPS DRUG DISCOVERY	128
NEW MARKET OPPORTUNITIES FOR UPS: PLANT BIOTECHNOLOGY AS A POTENTIAL MARKET FOR UPS	129
<i>TABLE 60 MARKET VALUE OF COTTON AND CORN IN THE U.S. (\$ BILLIONS)</i>	130
SIGNIFICANCE OF PATENTS IN UPS RESEARCH	130
<i>TABLE 61 PATENT APPLICATIONS FILED BY PHARMACEUTICAL COMPANIES DURING 2012</i>	131
<i>TABLE 62 PATENT APPLICATIONS FILED BY PHARMACEUTICAL COMPANIES DURING 2006</i>	132
<i>TABLE 63 NUMBER OF PATENT APPLICATIONS IN UBIQUITIN/ PROTEASOME RESEARCH FILED BY LEADING PHARMACEUTICAL COMPANIES, 1995-2013</i>	133
<i>FIGURE 8 NUMBER OF PATENT APPLICATIONS IN UBIQUITIN/PROTEASOME RESEARCH FILED BY LEADING PHARMACEUTICAL COMPANIES, 1995-2013 (NUMBER)</i>	134
<i>TABLE 64 PERCENTAGES OF PATENT APPLICATIONS IN UPS RESEARCH FILED IN THE U.S., EUROPE AND JAPAN (%)</i>	134
<b>CHAPTER 8 MARKET SUMMARY</b>	137
<i>TABLE 65 WORLDWIDE MARKET FOR VELCADE AND KYPROLIS, THROUGH 2018 (\$ MILLIONS)</i>	137
<i>FIGURE 9 WORLDWIDE MARKET FOR VELCADE AND KYPROLIS, 2010-2018 (\$ MILLIONS)</i>	138
<i>TABLE 66 DIFFERENT TARGETS OF UPS IN CURRENT DRUG DEVELOPMENT COMPANIES</i>	139
<i>TABLE 67 REAGENTS AND ASSAY DEVELOPMENT COMPANIES FOR UPS DRUG DISCOVERY</i>	139
<b>CHAPTER 9 SELECT COMPANIES AND PROFILES</b>	142
<b>CELGENE CORPORATION</b>	142
<b>ELAN PHARMACEUTICALS</b>	143
<b>GENENTECH (HOFFMANN-LA ROCHE AG)</b>	144



<b>TOPIC</b>	<b>PAGE NO.</b>
F. HOFFMANN-LA ROCHE LTD.	145
JOHNSON & JOHNSON	146
MILLENNIUM PHARMACEUTICALS: THE TAKEDA ONCOLOGY COMPANY	147
ONYX PHARMACEUTICALS INC.	147
PROGENRA	148
PROTEOLOGICS LTD.	149
PROTEOLOGICS LTD. (U.S.)	149
UBIQUIGENT LTD.	149
CHAPTER 10 LIST OF COMPANIES MENTIONED IN REPORT	152
ACENTA THERAPEUTICS	152
AEGERA THERAPEUTICS INC. (PART OF PHARMASCIENCE INC.)	152
AMGEN INC.	152
ASTELLAS PHARMA U.S. INC.	152
BIOGENOVA CORP.	152
BOSTON BIOCHEM INC. (R&D SYSTEMS)	153
BRISTOL-MYERS SQUIBB	153
CELGENE CORPORATION	153
CELLCENTRIC LTD.	153
CELLXPLORE	153
CISBIO	154
CLEAVE BIOSCIENCES	154
DUALSYSTEMS BIOTECH AG	154
ELAN PHARMACEUTICAL	154
ENZO LIFE SCIENCES INC.	154
GENENTECH INC. (ROCHE GROUP)	155
GSK (GLAXOSMITHKLINE PLC)	155
HYBRIGENICS	155
JOHNSON AND JOHNSON	155
F. HOFFMANN-LA ROCHE AG	155
LIFE SENSORS INC.	156
LIFE TECHNOLOGIES CORP. (THERMO FISHER SCIENTIFIC)	156
MESO SCALE DISCOVERY	156
MERCK CORPORATE HEADQUARTERS	156
MILLENNIUM PHARMACEUTICAL (THE TAKEDA ONCOLOGY COMPANY)	156
MISSION THERAPEUTICS LTD.	157
NEXUSPHARMA INC.	157
NOVARTIS INTERNATIONAL AG	157
ONYX PHARMACEUTICALS INC.	157
PRIAXON AG	157
PROGENRA INC.	158
PROTEOLOGICS LTD.	158
PROTEOSTASIS THERAPEUTICS	158
RIGEL PHARMACEUTICALS INC.	158
SCIL PROTEINS GMBH	158
SIGMA-ALDRICH	159
THERMO FISHER SCIENTIFIC INC.	159

<b>TOPIC</b>	<b>PAGE NO.</b>
TEVA PHARMACEUTICALS	159
TETRALOGICS PHARMACEUTICALS	159
UBIQ BIO BV	159
UBIQUIGENT LTD.	160

**LIST OF TABLES**

<b>TABLE HEADING</b>	<b>PAGE NO.</b>
SUMMARY TABLE GLOBAL MARKET FOR UBIQUITIN PROTEASOME RESEARCH AND DEVELOPMENT, THROUGH 2018 (\$ MILLIONS)	7
TABLE 1 ENZYMATIC COMPONENTS OF UBIQUITINATION/ DEUBIQUITINATION REACTION	11
TABLE 2 UBIQUITIN LIKE MODIFIERS (UBLs), THEIR FUNCTION AND ASSOCIATED SUBSTRATES	15
TABLE 3 U.S. STATISTICS FOR HEMATOLOGICAL MALIGNANCIES, 2011	21
TABLE 4 MARKET SIZE FOR MULTIPLE MYELOMA DRUG MARKET, THROUGH 2018 (\$ BILLIONS)	22
TABLE 5 EXAMPLE OF COST OF SIDE EFFECT FOR CHEMOTHERAPY TREATMENT IN 2006 IN U.S. PER PATIENT (\$ THOUSANDS)	25
TABLE 6 U.S. AND WORLDWIDE NET SALES FOR VELCADE, THROUGH 2018 (\$ MILLIONS)	26
TABLE 7 NET SALES FOR REVLIMID AND THALOMID, THROUGH 2018 (\$ MILLIONS)	28
TABLE 8 NET SALES FOR KYPROLIS, THROUGH 2018 (\$ MILLIONS)	31
TABLE 9 MARKET SHARE BETWEEN CELGENE AND MILLENIUM PHARMACEUTICALS/TAKEDA AND OTHER DRUG COMPANIES IN 2009, 2012 AGAINST POSSIBLE MARKET SHARE IN 2016 AND AFTER	33
TABLE 10 CURRENT R &D ACTIVITY IN UBIQUITIN/PROTEASOME RESEARCH IN MILLENIUM PHARMACEUTICALS	35
TABLE 11 COMPANIES WITH CURRENT R&D IN PROTEASOME INHIBITION AS A DRUG TARGET	37
TABLE 12 GENERAL MARKET WORTH FOR AUTOIMMUNE DISORDERS: LUPUS, RHEUMATOID ARTHRITIS AND IBD IN 2010 (\$ BILLIONS)	38
TABLE 13 ACTIVITY OF PROTEASOME INHIBITORS IN ANIMAL MODELS FOR AUTOIMMUNE AND INFLAMMATORY DISEASES	41
TABLE 14 MARKET SIZE FOR HAIR LOSS TREATMENT IN THE U.S. (\$ BILLIONS)	43
TABLE 15 GLOBAL MARKET SIZE FOR ANTI-AGING PRODUCTS (\$ BILLIONS)	44
TABLE 16 STATISTICS FOR TUBERCULOSIS INFECTION WORLDWIDE AND IN THE U.S., 2009 (MILLIONS)	45
TABLE 17 POTENTIAL MARKET WORTH FOR TUBERCULOSIS DRUG TREATMENT, 2009-2017 (\$ MILLIONS)	46
TABLE 18 MARKET SIZE FOR DRY EYE TREATMENT, 2009 AND 2013 (\$ BILLIONS)	46
TABLE 19 CURRENT DRUG DISCOVERY FOR E1 INHIBITORS	47
TABLE 20 E2S AS A DRUG DISCOVERY TARGET AND ITS MARKET POTENTIAL (\$ BILLIONS)	51
TABLE 21 MARKET POTENTIALS FOR SCA TREATMENT	52
TABLE 22 COMPANIES THAT WORK ON E3 LIGASES AS A DRUG TARGET	55
TABLE 23 DRUG DISCOVERY APPROACH FOR P53 STUDIES	65
TABLE 24 COMPANIES WITH R&D IN P53 GENE THERAPY	66
TABLE 25 U.S. STATISTICS AND GLOBAL MARKET SIZE FOR HEAD AND NECK AND OVARIAN CANCERS, 2009 (\$ MILLIONS)	67
TABLE 26 STRATEGIES FOR HDM2-P53 DRUG DISCOVERY	68
TABLE 27 LIST OF COMPANIES AND DRUG CANDIDATES IN HDM2/P53 DRUG DISCOVERY	69
TABLE 28 CURRENT COMPANIES WITH R&D PROGRAM IN IAP DRUG DISCOVERY	71
TABLE 29 POTENTIAL MARKET SIZE FOR IAPS DRUG DISCOVERY (\$ BILLIONS)	73
TABLE 30 LIST OF E3 UBIQUITIN LIGASES IN DRUG DISCOVERY	73
TABLE 31 STATISTICS FOR RA IN THE U.S. AND GLOBAL ESTIMATE FOR RA MARKET, 2009 AND 2030 (\$ BILLIONS)	76

<b>TABLE HEADING</b>	<b>PAGE NO.</b>
TABLE 32 STATISTICS FOR OSTEOPOROSIS IN THE U.S. AND GLOBAL ESTIMATE FOR OSTEOPOROSIS MARKET (\$ BILLIONS)	77
TABLE 33 POTENTIAL MARKETS FOR CURRENT PROJECTS IN E3 LIGASE DRUG DISCOVERY (\$ BILLIONS)	79
TABLE 34 ADDITIONAL E3 LIGASES AS POTENTIAL DRUG DISCOVERY TARGETS	79
TABLE 35 BREAST CANCER STATISTICS IN WOMEN IN THE U.S., 2009 (NUMBER OF NEW CASES)	81
TABLE 36 MARKET FOR BREAST CANCER THERAPEUTICS, THROUGH 2016 (\$ BILLIONS)	82
TABLE 37 DEUBIQUITINASES AND THEIR ROLE IN CLINICAL CONDITIONS	83
TABLE 38 EXAMPLES OF POTENTIAL MARKETS FOR DUBS DRUG DISCOVERY (\$ BILLIONS)	86
TABLE 39 EXAMPLES OF DUBS INHIBITORS AND THEIR TARGETS	87
TABLE 40 COMPANIES WORKING ON DUBS AS DRUG TARGET	89
TABLE 41 STATISTICS AND COST OF MEDICAL CARE IN LUNG AND COLON CANCER IN THE U.S., 2009 (\$ BILLIONS)	91
TABLE 42 ENZYMATIC MACHINERY OF SUMOYLATION	94
TABLE 43 GLOBAL BIOMARKERS MARKET, THROUGH 2015 (\$ BILLIONS)	98
TABLE 44 WORLDWIDE MARKET FOR BIOMARKERS ACCORDING TO DIFFERENT RESEARCH AREAS, 2013 (\$ BILLIONS/%)	98
TABLE 45 ANALYSIS OF SCIENTIFIC PUBLICATION ON UBIQUITIN PROTEASOME SYSTEM	101
TABLE 46 MARKET FOR BREAST CANCER DIAGNOSTICS, THROUGH 2016 (\$ BILLIONS)	103
TABLE 47 WORLDWIDE STATISTICS AND GLOBAL MARKET SIZE FOR MULTIPLE SCLEROSIS AND RHEUMATOID ARTHRITIS	103
TABLE 48 MARKET FOR IMMUNE DISORDERS DIAGNOSTICS (\$ BILLIONS)	105
TABLE 49 MARKET SIZE FOR REPRESENTATIVE NEURODEGENERATION DISORDERS AND STATISTICS OF INCIDENCE IN THE U.S.	106
TABLE 50 NET SALES OF REQUIP, 2010-2012 (\$ MILLIONS)	107
TABLE 51 NET SALES OF NAMENDA IN THE LAST THREE YEARS, 2010-2012 (\$ MILLIONS)	108
TABLE 52 STATISTICS FOR HUNTINGTON CONDITION IN THE U.S. AND GLOBAL MARKET SIZE FOR HUNTINGTON'S DISEASE	108
TABLE 53 STATISTICS AND COST OF IBD IN THE U.S.	110
TABLE 54 STATISTICS AND COST OF HCC IN USA	110
TABLE 55 COMPANIES INVOLVED IN MARKETING OF RESEARCH TOOLS FOR UPS, NUMBER OF PRODUCTS AND REVENUE OF THE COMPANY, 2010 (UNITS/\$ MILLIONS)	113
TABLE 56 EXAMPLE OF COMMON UPS REAGENTS PRICES IN MAJOR SUPPLIERS OF UPS REAGENT TOOL COMPANIES (\$)	117
TABLE 57 PROVIDERS OF SCREENING ASSAY TOOLS	118
TABLE 58 COMPANIES SELLING UBIQUITIN AND UBIQUITIN-LIKE MODIFIERS AS REAGENT TOOL FOR OTHER DRUG DISCOVERIES APPLICATIONS	123
TABLE 59 SCIENTIFIC AND TECHNOLOGICAL BREAKTHROUGHS IN UPS, 1977-2012	127
TABLE 60 MARKET VALUE OF COTTON AND CORN IN THE U.S. (\$ BILLIONS)	130
TABLE 61 PATENT APPLICATIONS FILED BY PHARMACEUTICAL COMPANIES DURING 2012	131
TABLE 62 PATENT APPLICATIONS FILED BY PHARMACEUTICAL COMPANIES DURING 2006	132
TABLE 63 NUMBER OF PATENT APPLICATIONS IN UBIQUITIN/ PROTEASOME RESEARCH FILED BY LEADING PHARMACEUTICAL COMPANIES, 1995-2013	133

<b>TABLE HEADING</b>	<b>PAGE NO.</b>
TABLE 64 PERCENTAGES OF PATENT APPLICATIONS IN UPS RESEARCH FILED IN THE U.S., EUROPE AND JAPAN (%)	134
TABLE 65 WORLDWIDE MARKET FOR VELCADE AND KYPROLIS, THROUGH 2018 (\$ MILLIONS)	137
TABLE 66 DIFFERENT TARGETS OF UPS IN CURRENT DRUG DEVELOPMENT COMPANIES	139
TABLE 67 REAGENTS AND ASSAY DEVELOPMENT COMPANIES FOR UPS DRUG DISCOVERY	139

**LIST OF FIGURES**

<b>FIGURE TITLE</b>	<b>PAGE NO.</b>
SUMMARY FIGURE GLOBAL MARKET FOR UBIQUITIN PROTEASOME RESEARCH AND DEVELOPMENT, 2010-2018 (\$ MILLIONS)	7
FIGURE 1 SCHEMATIC REPRESENTATION OF ENZYMATIC STEPS IN UBIQUITINATION REACTION	10
FIGURE 2 HIERARCHICAL STRUCTURE OF UBIQUITINE PROTEASOME SYSTEM	10
FIGURE 3 CHEMICAL STRUCTURE OF BORTEZOMIB	19
FIGURE 4 U.S. AND WORLDWIDE NET SALES FOR VELCADE, 2009-2018 (\$ MILLIONS)	26
FIGURE 5 NET SALES FOR REVLIMID AND THALOMID, 2009-2018 (\$ MILLIONS)	29
FIGURE 6 NET SALES FOR KYPROLIS, 2011-2018 (\$ MILLIONS)	31
FIGURE 7 EXAMPLE OF COMMON UPS REAGENTS PRICES IN MAJOR SUPPLIERS OF UPS REAGENT TOOL COMPANIES (\$)	117
FIGURE 8 NUMBER OF PATENT APPLICATIONS IN UBIQUITIN/PROTEASOME RESEARCH FILED BY LEADING PHARMACEUTICAL COMPANIES, 1995-2013 (NUMBER)	134
FIGURE 9 WORLDWIDE MARKET FOR VELCADE AND KYPROLIS, 2010-2018 (\$ MILLIONS)	138